Difference between revisions of "Part:BBa K4165145"
 
(One intermediate revision by one other user not shown)
Line 3: Line 3:
 
<partinfo>BBa_K4165145 short</partinfo>
 
<partinfo>BBa_K4165145 short</partinfo>
  
−
Tau binding peptide targeting the PHF seed of Tau
+
A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.
  
 
===Usage and Biology===
 
===Usage and Biology===
  
−
It is derived from D-enantiomeric peptide, its amino acid sequence is TTSLQMRLYYP. Its half maximal concentration for tau fibril formation inhibition is 7.9 μM, it can bind to tau at PHF seed VQIVYK. It can penetrate cell membrane and nuclei.  
+
TD peptide (TTSLQMRLYYP) derived from D-enantiomeric peptide acquired by mirror phage display. Its half maximal concentration for tau fibril formation inhibition is 7.9 μM, it can bind to tau at PHF seed VQIVYK and penetrate cell membrane and nuclei.  
 +
 
 +
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 +
<partinfo>BBa_K4165145 SequenceAndFeatures</partinfo>
  
 
===Dry Lab===
 
===Dry Lab===
Line 13: Line 16:
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 
modeled by AlphaFold2, Apptest, ITASSER, RosettaFold and TrRosetta, best model obtained from AlphaFold2  
 
modeled by AlphaFold2, Apptest, ITASSER, RosettaFold and TrRosetta, best model obtained from AlphaFold2  
−
 
−
 
−
 
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/td28.png" style="margin-left:200px;" alt="" width="300" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/td28.png" style="margin-left:300px;" alt="" width="300" /></p>
 
</html>
 
</html>
  
−
                            Figure 1.: Predicted 3D structure of Synthetic peptide TD28.
+
                              Figure 1.: Predicted 3D structure of Synthetic peptide TD28.
  
  
Line 28: Line 28:
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/td28-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/td28-qa.png" style="margin-left:50px;" alt="" width="800" /></p>
 
</html>
 
</html>
−
 
−
 
−
 
−
<!-- -->
 
−
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 
−
<partinfo>BBa_K4165145 SequenceAndFeatures</partinfo>
 
  
  

Latest revision as of 13:41, 11 October 2022


TD28 Peptide

A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.

Usage and Biology

TD peptide (TTSLQMRLYYP) derived from D-enantiomeric peptide acquired by mirror phage display. Its half maximal concentration for tau fibril formation inhibition is 7.9 μM, it can bind to tau at PHF seed VQIVYK and penetrate cell membrane and nuclei.

Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal PstI site found at 10
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal PstI site found at 10
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal PstI site found at 10
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal PstI site found at 10
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

modeled by AlphaFold2, Apptest, ITASSER, RosettaFold and TrRosetta, best model obtained from AlphaFold2 

                              Figure 1.: Predicted 3D structure of Synthetic peptide TD28.


Table 1: Quality assessment parameters of TD28 model.


References

1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.